What is the correct dosage of Dopamine Hydrochloride? Dopamine HCL is used for blood pressure in cases of shock, traumatic injury and surgery.
Unlike the neurotransmitter dopamine, this drug is not active in the brain. The dopamine HCL administered intravenously does not cross the blood brain barrier and does not affect mood or cognitive function.
For these applications, dopamine-boosting supplements are used. These supplements contain precursors of the dopamine neurotransmitter that boost levels within the brain.
In this article, we will discuss dosages used for Dopamine Hydrochloride as well as doses used for some popular dopamine-boosting supplements.



- Supports energy & motivation
- Promotes focus & mental clarity
- Improves mood & stress response
Dopamine Hydrochloride Dosage
Related Topics
Dopamine HCL (hydrochloride) comes in the form of a clear, aqueous solution. It is used intravenously after being diluted. Its scientific name is 3,4 dihydroxyphenethylamine hydrochloride.
Dopamine HCL is classified as an inotropic (modifies muscle contractility) vasopressor (constricts blood vessels) agent. It is useful for improving urine flow, blood flow to vital organs, blood pressure and overall cardiac function.
For treating nonobstructive oliguria in adults, an initial continuous IV infusion dosage of 1 to 5 mcg/kg/min is given. This dosage is then titrated until desired responses are achieved.
In life-threatening situations dopamine HCL dosage rates have exceeded 50 mcg/kg/min without causing serious adverse effects.
For treating pediatric nonobstructive oliguria, initial dopamine HCL dosages of 1 to 20 mcg/kg/min are delivered by continuous IV infusion. Titration to desired responses follows.
Similar dopamine HCL dosages are used to treat shock, heart attack, renal (kidney) failure and trauma.
Dopamine HCL should only be administered by a medical professional.
L-Tyrosine Dosage for Boosting Dopamine
L-tyrosine is a nonessential amino acid found in the diet. It is the natural chemical precursor of L-DOPA, the chemical used to synthesize dopamine.
L-tyrosine crosses the blood brain barrier and is then converted into L-DOPA via the actions of tyrosine hydroxylase. Then, L-DOPA is converted into dopamine by DOPA decarboxylase.
L-tyrosine supplementation is used for improving sociability, coping with stress, alleviating depression and boosting resistance to anxiety. It can also have broad mood enhancement effects.
Most people get enough L-tyrosine sources in the diet to avoid deficiency. However, taking a tyrosine supplement can increased brain dopamine levels, which may have benefits in certain cases.
For mood enhancement, it is commonly recommended to stack L-tyrosine supplements with 5-HTP (5-hydroxytryptophan). 5-HTP is the natural precursor for another important brain chemical called serotonin.
Research has shown that L-tyrosine is safe in daily doses between 200 mg and 5 g. When beginning to use any supplement, it is best to start at the low end of the dosage recommendations. The goal is to find the lowest dosage level that causes desired effects for you.
Some user reviews report noticeable effects with doses between 200 mg and 500 mg taken between one and three times daily. Other people use doses between 1 and 1.5 g, but that dosage level might be too high for some individuals.
L-tyrosine can be taken with or without food. Afternoon/evening use may interfere with sleeping patterns, so many users take tyrosine only in the mornings. Adverse side effects are rare when used appropriately, but may include headache, diarrhea, nausea, vomiting and insomnia.
Mucuna Pruriens Dosage
Mucuna pruriens is a natural plant that grows in West Africa. Its seeds have long been used for boosting dopamine levels.
Many people use M. pruriens to help alleviate depression and anxiousness. It is also used for reducing stress and enhancing mental focus.
Mucuna pruriens extracts contain about 5% natural L-DOPA. Unlike dopamine, L-DOPA is able to cross the Blood Brain Barrier. Once inside the brain, it is used to produce natural dopamine.
Mucuna supplements are also used for enhancing libido, increasing testosterone levels and supporting muscle mass gains. In folk medicine, this plant extract has been used as a natural therapy for Parkinson’s disease.
Taking a mucuna supplement may increase dopamine levels more than L-tyrosine by bypassing a rate-limiting factor in the production of dopamine within the brain. This could increase the risk of negative side effects; there is limited research available to rate the safety of this supplement.
The correct dose of mucuna extract to take will depend on the concentration of L-DOPA provided by the specific product you are using.
According to Ray Sahelian, MD, the recommended dose is one 200 mg capsule standardized to 15% L-DOPA, taken once or twice a day. This is an effective dosage of 30 – 60 mg of L-DOPA.
According to Dr. Sahelian, users should not take this supplement every day for long periods of time. Instead, he recommends taking a couple of days off a week to prevent changes in natural dopamine synthesis.
Daily doses in excess of 1 gram of raw mucuna extract are associated with heart palpitations, nausea, perspiration and hypertension (high blood pressure).
- Salinas AG1, Davis MI2, Lovinger DM2, Mateo Y3. Dopamine dynamics and cocaine sensitivity differ between striosome and matrix compartments of the striatum. Neuropharmacology. 2016 Mar 29. pii: S0028-3908(16)30121-6. doi: 10.1016/j.neuropharm.2016.03.049. [Epub ahead of print]
- Field T1, Hernandez-Reif M, Diego M, Schanberg S, Kuhn C. Cortisol decreases and serotonin and dopamine increase following massage therapy. Int J Neurosci. 2005 Oct;115(10):1397-413.
- Fernstrom JD1, Fernstrom MH Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr. 2007 Jun;137(6 Suppl 1):1539S-1547S; discussion 1548S.
- Liju, Vijayastelter B., Kottarapat Jeena, and Ramadasan Kuttan. "An Evaluation of Antioxidant, Anti-Inflammatory, and Antinociceptive Activities of Essential Oil from Curcuma Longa. L." Indian Journal of Pharmacology 43.5 (2011): 526–531. PMC. Web. 7 Apr. 2016.
- Wing VC1, Payer DE2, Houle S3, George TP4, Boileau I2. Measuring cigarette smoking-induced cortical dopamine release: A [¹¹C]FLB-457 PET study. Neuropsychopharmacology. 2015 May;40(6):1417-27. doi: 10.1038/npp.2014.327. Epub 2014 Dec 15.
- Kempster PA1, Gibb WR, Stern GM, Lees AJ. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry. 1989 Jan;52(1):72-6.
- Lou HC1. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. Acta Paediatr Suppl. 1994 Dec;407:86-8.
- Lucia Raffaella Lampariello,1 Alessio Cortelazzo,2 Roberto Guerranti,2 Claudia Sticozzi,3 and Giuseppe Valacchi3,4,* The Magic Velvet Bean of Mucuna pruriens Journal ListJ Tradit Complement Medv.2(4); Oct-Dec 2012PMC3942911
- Yokogoshi H1, Kobayashi M, Mochizuki M, Terashima T. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res. 1998 May;23(5):667-73.
- Janssen PA1, Leysen JE, Megens AA, Awouters FH. Does phenylethylamine act as an endogenous amphetamine in some patients? Int J Neuropsychopharmacol. 1999 Sep;2(3):229-240.
- Jiang H1, Wang J2, Rogers J3, Xie J4. Brain Iron Metabolism Dysfunction in Parkinson's Disease. Mol Neurobiol. 2016 Apr 2. [Epub ahead of print]
- Arnsten AF1, Girgis RR2, Gray DL3, Mailman RB4. Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biol Psychiatry. 2016 Jan 18. pii: S0006-3223(16)00044-5. doi: 10.1016/j.biopsych.2015.12.028. [Epub ahead of print]
- Arnsten AF1, Wang M2, Paspalas CD2. Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders. Pharmacol Rev. 2015 Jul;67(3):681-96. doi: 10.1124/pr.115.010512.
- Torres-Courchoud I1, Chen HH. Is there still a role for low-dose dopamine use in acute heart failure? Curr Opin Crit Care. 2014 Oct;20(5):467-71. doi: 10.1097/MCC.0000000000000133.
- Hu H1. Reward and Aversion. Annu Rev Neurosci. 2016 Apr 21. [Epub ahead of print]
- Solinas M1, Ferré S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci. 2002 Aug 1;22(15):6321-4.
- Volkow ND1, Wang GJ1, Logan J2, Alexoff D2, Fowler JS2, Thanos PK2, Wong C1, Casado V3, Ferre S4, Tomasi D1. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry. 2015 Apr 14;5:e549. doi: 10.1038/tp.2015.46.
Article last updated on: July 6th, 2018 by Nootriment